Gotham Therapeutics Raises $54M Series A To Target RNA-Modifying Proteins

Versant Ventures seed company Gotham Therapeutics emerges from stealth mode to develop novel class of drugs targeting RNA-modifying proteins with backing from co-leads Versant, Forbion and SR One.

At the heart of the newco is the knowledge that messenger RNA can be subjected to a variety of post-transcriptional modifications that markedly influence their fate and function particularly when it comes to health and disease. Seeded initially with money from Versant Ventures, a team at Cornell University, led by professor Samie Jaffrey, has secured $54m in a Series A round to develop drugs that target key mRNA modulating proteins.

The Series A round has attracted Versant Ventures, Forbion and SR One as co-leads and includes Celgene and Alexandra Venture...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

More from Business

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

 
• By 

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By 

Paying €90m upfront for rights to generalized pustular psoriasis drug.